- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Facing Shortage, Novo Nordisk Halts All Marketing for Wegovy
Advertising pause aims to prevent stimulating further demand, company says.
Novo Nordisk, a Danish pharmaceutical company, is pausing all advertising efforts for Wegovy, a drug prescribed for obesity, in an effort to curb growing demand. The organization believes that the popularity of this medication is due to its promotion as a weight-loss panacea by influencers on social media, mainly TikTok.
In addition to slowing down advertisements, there have been production issues. In April, Novo said it would increase the supply of Wegovy after initial contract manufacturing difficulties.
According to the company, promotional efforts aimed at healthcare professionals are also being assessed for potential adjustments.
Reference: Shortage of Wegovy Leads Novo Nordisk to Pause All Advertisements. May 23, 2023/Health News
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
